Three Key EU Actions Needed On Coronavirus
Medicines For Europe Urges Supply Measures, Guidance And Scenario Planning
Immediate EU-wide measures are needed to ensure the supply of medicines, according to off-patent industry association Medicines for Europe, which has also called for clear regulatory guidance and scenario planning to address the challenges posed by the coronavirus outbreak.
You may also be interested in...
European off-patent industry association Medicines for Europe has called on the European Commission to urgently establish a “structured dialog” involving industry stakeholders, to help plan for an extended outbreak of coronavirus.
As part of its response to the coronavirus outbreak, Medicines for Europe has set out a series of policy recommendations that it says could help to mitigate the risks of COVID-19.
Teva is gearing up to introduce the Ongavia ranibizumab biosimilar in the UK, following an approval by the local regulator ahead of its European counterpart. The development means the Israeli firm and partners Bioeq and Formycon could secure a global first launch of a rival to Lucentis, ahead of expected imminent launches by Samsung Bioepis of its Byooviz version in the US and Europe.